Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Smith JW 2nd, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, Fisher B, Justice L, Wood W, Vetto J, Maecker H, Dols A, Meijer S, Hu HM, Romero P, Alvord WG, Urba WJ. Smith JW 2nd, et al. Among authors: doran t. J Clin Oncol. 2003 Apr 15;21(8):1562-73. doi: 10.1200/JCO.2003.09.020. J Clin Oncol. 2003. PMID: 12697882 Clinical Trial.
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results.
Dols A, Smith JW 2nd, Meijer SL, Fox BA, Hu HM, Walker E, Rosenheim S, Moudgil T, Doran T, Wood W, Seligman M, Alvord WG, Schoof D, Urba WJ. Dols A, et al. Among authors: doran t. Hum Gene Ther. 2003 Jul 20;14(11):1117-23. doi: 10.1089/104303403322124828. Hum Gene Ther. 2003. PMID: 12885350 Clinical Trial.
Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW, Kurt RA, Baher AG, Denman S, Justice L, Doran T, Gilbert M, Alvord WG, Urba WJ. Smith II JW, et al. Among authors: doran t. J Immunother. 2003 Mar-Apr;26(2):130-8. doi: 10.1097/00002371-200303000-00005. J Immunother. 2003. PMID: 12616104 Clinical Trial.
Examining the immune response in sentinel lymph nodes of mice and men.
Chu Y, Hu HM, Winter H, Wood WJ, Doran T, Lashley D, Bashey J, Schuster J, Wood J, Lowe BA, Vetto JT, Weinberg AD, Puri R, Smith JW 2nd, Urba WJ, Fox BA. Chu Y, et al. Among authors: doran t. Eur J Nucl Med. 1999 Apr;26(4 Suppl):S50-3. doi: 10.1007/s002590050578. Eur J Nucl Med. 1999. PMID: 10199933
Immunological and molecular analysis of the sentinel lymph node: a potential approach to predict outcome, tailor therapy, and optimize parameters for tumor vaccine development.
Meijer SL, Dols A, Hu HM, Jensen S, Poehlein CH, Chu Y, Winter H, Yamada J, Moudgil T, Wood WJ, Doran T, Justice L, Fisher B, Wisner P, Wood J, Vetto JT, Mehrotra R, Rosenheim S, Weinberg AD, Bright R, Walker E, Puri R, Smith JW 2nd, Urba WJ, Fox BA. Meijer SL, et al. Among authors: doran t. J Clin Pharmacol. 2001 Jul;41(S7):81S-94S. J Clin Pharmacol. 2001. PMID: 11452734 Review. No abstract available.
380 results